GLP1 Guide (Page 3)

category:news

A new risk: Kidney Cancer

New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.

malady:addiction

GLP1s vs. Addiction, a quick review

We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.

drug:retatrutide

An update on Retatrutide (May 2025)

We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.

category:benefits

GLP1s lower inflammation, Psoriasis, AND increase fertility?

We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.

politics

GLP1s and Tariffs, the story so far

We take a look at the various movements in GLP1 policy by the Trump administration, so far.

drug:wegovy

Wegovy in pill form is coming

Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.

drug:nimacimab

Boosting Tirzepatide with Nimacimab

Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.

company:eli-lilly

Eli Lilly suing GLP1 compounders & related companies

Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.

company:pfizer

Pfizer ends development of oral GLP1 Danuglipron

Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.

drug:mounjaro

Mounjaro's India launch

Eli Lilly's Mounjaro launches in India